Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME9JNL)

• Drug Name: Propericiazine Drug Info
• Synonyms: Aolept; Nemactil; Neulactil; Neuleptil; PERICYAZINE; Periciazina; Periciazine; Periciazinum; Piperocyanomazine;Periciazine [INN]; Bayer 1409; IC 6002; RP 8908; WH 7508; Neulactil (TN); Neuleptil (TN); Periciazina [INN-Spanish]; Periciazinum [INN-Latin]; Propericiazine (JAN); Propericiazine(jan); SKF 20,716; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine [French]; 10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile; 10-[3-(4-hydroxypiperidin-1-yl)propyl]-10H-phenothiazine-2-carbonitrile; 10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile; 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine; 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine; 6909 RP

Indication

Disease Entry	ICD 11	Status	REF
Psychiatric disorder	6E8Z	Approved	[1]

• Therapeutic Class: Antipsychotic Agents
• Cross-matching ID:
  PubChem CID: 4747
  ChEBI ID: CHEBI:31981
  CAS Number: CAS 2622-26-6
  TTD Drug ID: DME9JNL
  INTEDE Drug ID: DR2300

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-1B (ADRA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methamphetamine	DMPM4SK	Anxiety		Approved	[4]
Methoxamine	DMF5XQH	Hypertension	BA00-BA04	Approved	[5]
Phendimetrazine	DM6TS1N	Obesity	5B81	Approved	[6]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[7]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[8]
Sunepitron	DM6M8ZX	N. A.	N. A.	Discontinued in Phase 3	[9]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[10]
SOU-001	DMPAEK5	Urinary incontinence	MF50.2	Discontinued in Phase 2	[11]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[12]
WB-4101	DMQU8B1	N. A.	N. A.	Terminated	[13]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[14]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[15]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[16]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[17]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[17]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[18]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[19]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[20]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[21]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1B (ADRA1B)	TTBRKXS	ADA1B_HUMAN	Binder	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[3]

References

• [1] Drug Information of Troleandomycin from nextbio research in illumina. 2015.
• [2] Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
• [3] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [4] Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
• [5] Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
• [6] Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
• [7] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [8] 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
• [9] An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
• [10] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [11] Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
• [12] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [13] Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
• [14] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [15] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [16] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [17] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [18] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [19] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [20] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [21] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.